EQUIMUCIN 2G ORAL POWDER FOR HORSES
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
04-06-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
ACETYLCYSTEINE
Available from:
CP-Pharma Handelsgesellschaft mbH
ATC code:
QR05CB01
Dosage:
2 Grams
Pharmaceutical form:
Oral Powder
Therapeutic group:
Respiratory Tract Preparations
Therapeutic area:
Equine - Food
Authorization date:
2004-08-06
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Equimucin 2g, Oral Powder for Horses.
Acetylcysteine.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
White to pale yellow oral powder
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horse
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Reduction of viscosity of the tracheobronchial secretion in the supportive mucolytic treatment of chronic broncho-
pulmonary diseases accompanied by abnormal secretion and mucostasis in the horse.
4.3 CONTRAINDICATIONS
Do not administer the product in case of known hypersensitivity to acetylcysteine.
See also section 4.8.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
The product should not be used in horses suspected of suffering from gastric ulceration.
As acetylcysteine is metabolised to sulphur containing products, use cautiously in horses known to be suffering from
liver disease.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS
Persons should wear gloves during administration.
1 sachet of 6g oral powder contains:
ACTIVE SUBSTANCE
Acetylcysteine
2000 mg
For a full list of excipients, see section 6.1.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 30/08/2011_
_CRN 7010648_
_page number: 1_
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Hypersensitivity to acetylcysteine may occur.
Should undesirable effects occur, withdraw the product and treat symptomatically.
4.7 USE DURING PREGNANCY, LACTATION OR LAY
Laboratory studies in rats and rabbits have not produced any evidence of a teratogenic effect. Safety of the product has
not been established durin
Read the complete document
